Cipher Pharmaceuticals Inc. (CPHRF)

Cipher Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	22.25	21.55	20.68	21.94	21.61	22.45
Revenue Growth (YoY)	10.46%	4.23%	-5.78%	1.56%	-3.76%	-1.31%
Cost of Revenue	4.74	5.39	3.99	3.68	3.06	2.91
Gross Profit	17.52	16.16	16.68	18.26	18.55	19.55
Selling, General & Admin	5.97	5.8	5.54	5.11	6.26	7.65
Research & Development	0.18	0.14	0.1	0.09	0.13	0.4
Other Operating Expenses	0	0	0	1.25	0	0
Operating Expenses	6.72	5.94	5.63	6.45	6.39	8.04
Operating Income	10.78	10.22	11.09	11.82	12.2	11.68
Interest Income	2.09	1.9	0.45	0.01	0.03	0.18
Interest Expense	0	0	-0.39	0.09	0.32	0.97
Other Expense / Income	0.03	-0.42	0.45	0.68	5.21	4.58
Pretax Income	13.03	12.91	11.48	11.06	6.54	5.71
Income Tax	-9.84	-7.84	-15.16	3.3	2.15	3.07
Net Income	22.68	20.38	26.64	7.76	4.55	3.24
Net Income Growth	-16.35%	-23.48%	243.34%	70.54%	40.31%	497.05%
Shares Outstanding (Basic)	24	25	25	27	27	27
Shares Outstanding (Diluted)	24	25	26	27	27	27
Shares Change	-4.53%	-1.46%	-3.84%	-1.96%	1.52%	-0.15%
EPS (Basic)	0.92	0.83	1.01	0.29	0.18	0.12
EPS (Diluted)	0.92	0.82	0.99	0.29	0.18	0.12
EPS Growth	-14.26%	-17.17%	241.38%	61.11%	50.00%	497.01%
Free Cash Flow	13.68	16.15	10.49	13.81	10.93	7.55
Free Cash Flow Per Share	0.56	0.64	0.41	0.51	0.40	0.28
Gross Margin	78.71%	74.97%	80.69%	83.21%	85.85%	87.06%
Operating Margin	48.44%	47.41%	53.62%	53.87%	56.44%	52.03%
Profit Margin	101.92%	94.58%	128.83%	35.36%	21.05%	14.44%
Free Cash Flow Margin	61.46%	74.92%	50.76%	62.95%	50.59%	33.62%
Effective Tax Rate	-75.52%	-60.74%	-132.04%	29.85%	32.89%	53.78%
EBITDA	11.96	11.47	12.07	12.52	13.4	12.87
EBITDA Margin	53.74%	53.21%	58.40%	57.07%	62.02%	57.32%
Depreciation & Amortization	1.18	1.25	0.99	0.7	1.21	1.19
EBIT	10.78	10.22	11.09	11.82	12.2	11.68
EBIT Margin	48.44%	47.41%	53.62%	53.87%	56.44%	52.03%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.